YARTEMLEA's commercial ramp and pending EU approval test whether first-mover monopoly in TA-TMA can sustain Omeros through pipeline maturation

Bull

A positive CHMP opinion leading to European Commission approval would grant YARTEMLEA exclusive access to the EU/EEA TA-TMA market with no approved competitors, replicating the U.S. monopoly position across a major second geography. This would significantly expand peak sales estimates, strengthen Omeros's negotiating position with EU payers, and de-risk the pipeline maturation timeline by broadening the revenue base supporting ongoing R&D spend.

Bear

The CHMP could issue a negative opinion or request additional data — particularly given that the pivotal trial enrolled only 28 patients and the single-arm design lacks a randomized comparator, which European regulators may scrutinize more stringently than the FDA did. A request for a major objection response or a full refusal could delay EU revenue by one to several years, undermining the commercial ramp thesis and raising questions about whether U.S. sales alone can sustain the company through pipeline maturation.